Luxación congénita familiar de la cabeza radial

Presentamos un caso de luxación congénita familiar de la cabeza radial. Suele ser una entidad asintomática, y puede conducir a dudas diagnósticas cuando se observa tras un traumatismo. Los antecedentes familiares y la radiografía del codo contralateral son útiles en la diferenciación frente a una luxación traumática. El tratamiento habitual de la luxación congénita de cabeza radial asintomática es la observación.A case of familiar congenital dislocation of the radial head is presented. It used to be an asymptomatic entity, and may lead to misdiagnosis when it is observed after a traumatism. Familiar history and contralateral radiographs are useful in the differentiation from a traumatic dislocation. The standard treatment for asymptomatic congenital radial head dislocations is observation

Complicaciones a corto plazo de la artroplastia total primaria de cadera

Objetivos: Se pretende analizar las principales complicaciones a corto plazo (seis semanas) tras la Artroplastia total primaria de cadera. ;aterial y métodos: Se revisaron todos los pacientes a los que se realizó artroplastia total de cadera durante el año 2003. Las variables estudiadas fueron el índice de luxaciones, sangrado, infección, fracturas periprotésicas, complicaciones vásculo-nerviosas y mortalidad. Resultados: Obtuvimos una tasa del 4,4% de luxaciones; 1,7% de trombosis venosa profunda con un 0,87% de embolismo pulmonar, 1,7% de infecciones superficiales sin casos de infección profunda. El 14,9% de los casos necesitaron una transfusión postquirúrgica. Intraoperatoriamente observamos apertura del cálcar en el 3,5%, y fracturas periprotésicas postoperatorias en el 0,87%. No registramos complicaciones neurológicas ni mortalidad en estas primeras seis semanas del estudio. Conclusiones: La complicación más frecuente es la luxación, fundamentalmente en los casos secundarios a fractura. La trombosis venosa profunda, a èsar de la profilaxis, continúa siendo una complicación frecuente.Objectives: Our purpose was to analyze the main early complications (six weeks) after primary total hip arthroplasty. Materials and Methods: All patients who had undergone primary total hip replacement during 2003 were reviewed. The studied outcomes were the rates of dislocation, blood loss, infection, periprosthetic fractures, neural and vascular complications, and mortality. Results: Our rates were 4,4% for hip dislocation, 1,7% for deep vein thrombosis with 0,87% for pulmonary embolism, 1,7% for wound infection without cases of deep infection. 14,9% of the patients needed postoperative transfusion. We reported 3,5% fractures of the calcar during surgery and 0,87% of postoperative periprosthetic fractures. We didn ́t reported any neural complications or mortality within six weeks postoperatively. Conclusions: The most frequent complication is dislocation, mainly in cases whose underlying diagnose was hip fracture. Although prophylaxis is done, deep vein thrombosis goes on being a frequent complication

Melatonin modulation of radiation-induced molecular changes in MCF-7 human breast cancer cells

Radiation therapy is an important component of cancer treatment scheduled for cancer patients, although it can cause numerous deleterious effects. The use of adjuvant molecules aims to limit the damage in normal surrounding tissues and to enhance the effects of radiation therapy either killing tumor cells or slowing down their growth. Melatonin, an indoleamine released by the pineal gland, behaves as a radiosensitizer in breast cancer since it enhances the therapeutic effects of ionizing radiation and mitigates side effects on normal cells. However, the molecular mechanisms through which melatonin modulates the molecular changes triggered by radiotherapy remain mostly unknown. Here we report that melatonin potentiated the antiproliferative effect of radiation in MCF-7 cells. Treatment with ionizing radiation induced changes in expression of many genes. Out of a total of twenty-five genes altered by radiation, melatonin potentiated changes in thirteen of them, whereas reverted the effect in another ten cases. Among them, melatonin elevated the levels of PTEN and NME1, whereas counteracted the induction by radiation of SNAI2, ERBB2, AKT, SERPINE1, SFN, PLAU, ATM and N3RC1. We also analyzed the expression of several microRNAs and found that melatonin enhanced the effect of radiation on the levels of miR-20a, miR-19a, miR-93, miR-20b, miR-29a. Rather surprisingly, radiation induced miR-17, miR-141 and miR-15a but melatonin treatment prior to radiation counteracted this stimulatory effect. Radiation alone enhanced the expression of the cancer suppressor miR-34a, and melatonin strongly stimulated this effect. Melatonin further enhanced the radiationmediated inhibition of Akt. Finally, in an in vivo assay, melatonin restrained new vascularization in combination with ionizing radiation. Our results confirm that melatonin blocks many of the undesirable effects of ionizing radiation in MCF-7 cells and enhances changes that lead to optimed treatment resultsAcknowledgments: The present study was funded by grants from the Spanish Economy and Competitiveness Ministry (SAF2016-77103-P), from Universidad de Cantabria (Proyectos Puente 2020) with the participation of the Consejería de Universidades, Igualdad, Cultura y Deporte del Gobierno de Cantabria, and from Instituto de Investigación Sanitaria Valdecilla (IDIVAL) (APG/12)

Characterization of a new albendazole resistant Fasciola hepatica isolate

Characterization of a new albendazole resistant Fasciola hepatica isolateMaría Martínez-Valladares11,2, Elora Valderas-García1,2, Verónica Castilla Gómez de Agüero1,2, Marta González-Warleta3, Laura Ceballos4, Juan P. Lirón4, Rodrigo Sanabria5, Cesar Pruzzo5, Luis I. Alvarez4.1Instituto de Ganadería de Montaña (CSIC-Universidad de León), Departamento de Sanidad Animal (Department of Animal Health), León, Spain.2Departamento de Sanidad Animal (Department of Animal Health), Facultad de Veterinaria, University of Leon, Leon, Spain.3Laboratorio de Parasitología, Centro de Investigaciones Agrarias de Mabegondo, AGACAL, Abegondo, A Coruña, Spain.4Laboratorio de Farmacología, Centro de Investigación Veterinaria de Tandil (CIVETAN), UNCPBA-CICPBA-CONICET, Facultad de Ciencias Veterinarias, Tandil, Argentina.5Laboratorio de Parasitología, Facultad de Ciencias Veterinarias, Universidad Nacional de la Plata (UNLP), La Plata, Argentina.The infection by Fasciola hepatica affects mainly ruminants although is present in a wide variety of species including humans. Fasciolosis control is mainly based on triclabendazole administration, the main drug indicated in humans. Albendazole (ABZ) is used against nematode and liver fluke infections in ruminants. The misuse of these drugs has led to the appearance of anthelmintic resistance. In this study, we characterized an ABZ resistant isolate and evaluate the use of a combined treatment to improve treatment efficacy. The isolate was collected from a slaughterhouse in Argentina, maintained under laboratory conditions and identified by means of the egg hatch test (EHT). Using these eggs metacercariae were produced to infect sheep artificially. When flukes reached the adult stage, animals were divided into two groups, one treated with ABZ (7.5 mg/kg bw) and another with a placebo. All sheep were slaughtered at day 14 post-treatment to collect and count the number of flukes. The resistance of ABZ was confirmed with a reduction of 44% of adult flukes in the treated group. At the necropsy, adult flukes from the livers and eggs from the gall bladders, both from sheep treated with the placebo, were collected. Adult flukes were maintained alive in RPMI medium to let them to excrete eggs for 24 hours. EHT was conducted and different results were observed with the two egg sets. The EHT performed with eggs collected directly from gall bladder confirmed the resistant status of the isolate. However, the EHT with eggs recovered from flukes resulted in a susceptible phenotype, showing that only previously laying eggs (in bile) can express the resistant phenotype. After producing more metacercariae from this resistant isolate, we are testing in vivo the efficacy of a combined treatment to improve its efficacy. The results will be presented during the WAAVP meeting.Fil: Martínez Valladares, María. Universidad de Leon. Facultad de Veterinaria; ArgentinaFil: Valderas García, Elora. Universidad de Leon. Facultad de Veterinaria; ArgentinaFil: Castilla Gómez de Agüero, Verónica. Universidad de Leon. Facultad de Veterinaria; ArgentinaFil: González Warleta, Marta. Universidad de Leon. Facultad de Veterinaria; ArgentinaFil: Ceballos, Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Liron, Juan Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Sanabria, Rodrigo. Universidad Nacional de La Plata. Facultad de Ciencias Veterinarias; ArgentinaFil: Pruzzo, Cesar Ivan. Universidad Nacional de La Plata. Facultad de Ciencias Veterinarias; ArgentinaFil: Alvarez, Luis Ignacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina28th International Conference of tha World Association for the Advancement of Veterinary ParasitologyDublinIrlandaWorld Association for the Advancement of Veterinary ParasitologyUniversity College Dubli

Association of IFN-γ +874 A/T SNP and hypermethylation of the -53 CpG site with tuberculosis susceptibility

Introduction: Tuberculosis (TB) is now the 2nd leading infectious killer after COVID-19 and the 13th leading cause of death worldwide. Moreover, TB is a lethal combination for HIV-patients. Th1 responses and particularly IFN-γ are crucial for immune protection against Mycobacterium tuberculosis infection. Many gene variants for IFNG that confer susceptibility to TB have been described in multiple ethnic populations. Likewise, some epigenetic modifications have been evaluated, being CpG methylation the major epigenetic mark that makes chromatin inaccessible to transcription factors, thus avoiding the initiation of IFNG transcription. Methods: We evaluated both genetic and epigenetic changes involved in IFN-γ production and TB susceptibility in Argentine population. Amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) was performed for the IFN-γ +874 A/T polymorphism (rs2430561) genotyping in 199 healthy donors (HD) and 173 tuberculosis (TB) patients. IFN-γ levels from M. tuberculosis-stimulated PBMCs were measured by ELISA. The methylation status at the -53 CpG site of the IFNG promoter in individuals with latent infection (LTBI), TB and HD was determine by pyrosequencing. Results: Using a case-control study, we found that A allele and, consequently, AA genotype were overrepresented in patients with active disease. Moreover, HD carrying T allele (AT or TT genotype) evidenced an augmented IFN-γ secretion compared to TB patients. Codominance was the genetic model that best fits our results according to the Akaike information criterion (AIC). In addition, increased methylation levels at the -53 CpG site in the IFN-γ promoter were observed in whole blood of patients with active TB compared to LTBI individuals. Discussion: IFN-γ is regulated by genetic variants and epigenetic modifications during TB. Besides, AA genotype of the rs2430561 single nucleotide polymorphism could be considered as a potential TB susceptibility genetic biomarker in Argentina and the methylation of the -53 CpG site could result in a useful predictor of TB reactivation.Fil: Alvarez, Guadalupe Inés. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires. Universidad Nacional del Noroeste de la Provincia de Buenos Aires. Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; ArgentinaFil: Hernández del Pino, Rodrigo Emanuel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires. Universidad Nacional del Noroeste de la Provincia de Buenos Aires. Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires; ArgentinaFil: Barbero, Angela Maria. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires. Universidad Nacional del Noroeste de la Provincia de Buenos Aires. Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires; ArgentinaFil: Estermann, Martín Andrés. Universidad Nacional del Noroeste de la Provincia de Buenos Aires; ArgentinaFil: Celano, Josefina. Universidad Nacional del Noroeste de la Provincia de Buenos Aires; ArgentinaFil: Musella, Rosa María. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas "Dr. Francisco Javier Muñiz"; ArgentinaFil: Palmero, Domingo Juan. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas "Dr. Francisco Javier Muñiz"; ArgentinaFil: García, Verónica Edith. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; ArgentinaFil: Pasquinelli, Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires. Universidad Nacional del Noroeste de la Provincia de Buenos Aires. Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires; Argentin

Gene expression profiles induced by E6 from non-European HPV18 variants reveals a differential activation on cellular processes driving to carcinogenesis

AbstractCervical cancer in developed countries remains as a major concern on public health policies due to incidence and mortality rates. Persistent infection with high risk human papillomavirus is a necessary etiological agent in the progression to invasive cervical carcinoma. A proposed hypothesis is the association between more aggressive HPV variants and the risk to develop cervical cancer. In order to have a global perspective in terms of cellular transcripts and molecular pathways affected by HPV18 E6 intratype variants; we conducted a genome wide analysis of gene expression. Our results show that E6 derived from non-European variants are able to up-regulate cellular transcripts associated to the hallmarks of cancer; such as cell cycle, migration, Wnt pathway and mTor signaling. Moreover, we were able to show that HPV18 E6 from African variant had a major effect on cellular processes such as cell cycle and migration as confirmed by functional studies

Interlaboratory analytical validation of a Next-generation sequencing strategy for clonotypic assessment and minimal residual disease monitoring in multiple myeloma

[Context]: Minimal residual disease (MRD) is a major prognostic factor in multiple myeloma, although validated technologies are limited. [Objective]: To standardize the performance of the LymphoTrack next-generation sequencing (NGS) assays (Invivoscribe), targeting clonal immunoglobulin rearrangements, in order to reproduce the detection of tumor clonotypes and MRD quantitation in myeloma. [Design]: The quantification ability of the assay was evaluated through serial dilution experiments. Paired samples from 101 patients were tested by LymphoTrack, using Sanger sequencing and EuroFlow's next-generation flow (NGF) assay as validated references for diagnostic and follow-up evaluation, respectively. MRD studies using LymphoTrack were performed in parallel at 2 laboratories to evaluate reproducibility. [Results]: Sensitivity was set as 1.3 tumor cells per total number of input cells. Clonality was confirmed in 99% and 100% of cases with Sanger and NGS, respectively, showing great concordance (97.9%), although several samples had minor discordances in the nucleotide sequence of rearrangements. Parallel NGS was performed in 82 follow-up cases, achieving a median sensitivity of 0.001%, while for NGF, median sensitivity was 0.0002%. Reproducibility of LymphoTrack-based MRD studies (85.4%) and correlation with NGF (R2 > 0.800) were high. Bland-Altman tests showed highly significant levels of agreement between flow and sequencing. [Conclusions]: Taken together, we have shown that LymphoTrack is a suitable strategy for clonality detection and MRD evaluation, with results comparable to gold standard procedures. Multiple myeloma (MM) is a plasma-cell dyscrasia characterized by the accumulation of plasma cells in the bone marrow that produces an excess of clonal immunoglobulins (M-protein or monoclonal component).1 New treatment approaches have increased the number of patients achieving complete response (CR),2–5 progressively improving progression-free and overall survival rates in the last 10 years.6–11 Nonetheless, the presence of low levels of drug-resistant cells (known as minimal residual disease, MRD)12–14 that remain undetected by conventional serologic and morphologic methods explains frequent relapses with this disease, which is still considered an incurable illness.Minimal residual disease is currently considered one of the most informative prognostic parameters, since those patients with undetectable disease have shown prolonged survival rates as compared with MRD-positive patients,15–17 and this difference is still significant even when patients achieving only stringent complete response (sCR) are taken into account.18 The International Myeloma Working Group (IMWG) defined MRD positivity as the persistence of clonal malignant plasma cells assessed with a sensitivity of at least 10−5 (1 malignant cell per hundred thousand normal cells)19 ; therefore, MRD should be monitored with only highly sensitive methods. To date, 3 different approaches have been tested for MRD monitoring in hematologic malignancies: immunophenotypic (multiparametric flow cytometry [MFC]),20 molecular (quantitative polymerase chain reaction [PCR], next-generation sequencing [NGS], digital PCR),21–23 and imaging tools (positron emission tomography–computed tomography; magnetic resonance imaging).24,25 However, in MM standardization has been achieved only for MFC26 and NGS.27,28 As a result, the IMWG recommended the use of highly sensitive, standardized flow and sequencing approaches,19 including EuroFlow's next-generation flow (NGF)29 and Adaptive Biotechnologies' ClonoSEQ solutions (Adaptive Biotechnologies, Seattle, Washington). NGF is a 2-tube, 8-color flow assay that allows the simultaneous analysis of 10 million cells, providing a sensitivity of around 2·10−6.This work was partially supported by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness PI15/01956, CIBERONC-CB16/12/00233, and “Una manera de hacer Europa” (Innocampus; CEI-2010-1-0010). García-Álvarez, Prieto-Conde, and Jiménez were supported by the Fundación Española de Hematología y Hemoterapia (FEHH, cofunded by Fundación Cris in the latter case), Medina by the European Social Fund through the University of Salamanca and the ISCIII (FI19/00320), and Sarasquete by the ISCIII (CPII18/00028). All Spanish funding is cosponsored by the European Union FEDER program

Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping

The Hodgkin lymphoma (HL) genomic landscape is hardly known due to the scarcity of tumour cells in the tissue. Liquid biopsy employing circulating tumour DNA (ctDNA) can emerge as an alternative tool for non-invasive genotyping. By using a custom next generation sequencing (NGS) panel in combination with unique molecule identifiers, we aimed to identify somatic variants in the ctDNA of 60 HL at diagnosis. A total of 277 variants were detected in 36 of the 49 samples (73·5%) with a good quality ctDNA sample. The median number of variants detected per patient was five (range 1–23) with a median variant allele frequency of 4·2% (0·84–28%). Genotyping revealed somatic variants in the following genes: SOCS1 (28%), IGLL5 (26%), TNFAIP3 (23%), GNA13 (23%), STAT6 (21%) and B2M (19%). Moreover, several poor prognosis features (high LDH, low serum albumin, B-symptoms, IPI ≥ 3 or at an advanced stage) were related to significantly higher amounts of ctDNA. Variant detection in ctDNA by NGS is a feasible approach to depict the genetic features of HL patients at diagnosis. Our data favour the implementation of liquid biopsy genotyping for the routine evaluation of HL patients.This work was partially supported by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness CIBERONC-CB16/12/00233, and “Una manera de hacer Europa” (Innocampus; CEI-2010-1-0010)”, the Health Council of the Junta de Castilla y León (GRS2037/A/19) (GRS1845/A/18) and private Gilead (GLD/18/00063). MGA is supported with a grant from the Accelerator consortia (Cancer Research UK; C355/A26819). CJ and AM are supported by the ISCII (CD19/00030 and FI19/00320). MES is supported by Contrato Miguel Servet tipo II (CPII18/00028). MA is financed by CIBER-CB16/12/00233. All Spanish funding is co-sponsored by the European Union FEDER program

Análisis genómico de dos cepas de K. pneumoniae ST11 resistentes a colistina portadoras de blaNDM-5 en una plataforma genética asociada a los integrones complejos de clase 1, con fenotipo de extrema resistencia a antibióticos

La metalo-β-lactamasa de Nueva Delhi (NDM) otorga resistencia a la mayoría de los antibióticos β-lactámicos, y generalmente se encuentra en aislamientos que poseen otros genes de resistencia (GRA) a otras familias de antibióticos. Estos aislamientos multidroga resistentes o con extrema resistencia, causan una variedad de infecciones asociadas con altas tasas de mortalidad en el ambiente hospitalario. Aunque el alelo NDM-1 es el más prevalente, otras variantes están aumentando su frecuencia en todo el mundo. En nuestro país se reportó recientemente el primer aislamiento clínico de Escherichia coli, Ec265, productora de NDM-5 y RmtB en América Latina. En nuestro estudio, se identificaron ambos genes blaNDM-5, y rmtB en dos cepas de Klebsiella pneumoniae aisladas de una mujer de 83 años en el año 2018. El primer aislamiento correspondió aun hisopado rectal que se tomó el primer día de ingreso al hospital dentro del programa de vigilancia. Se aisló la cepa H30pKpn productora de metalo-β-lactamasa y, en consecuencia, se instalaron las precauciones de contacto. Al cuarto día de hospitalización inició con fiebre, tos productiva y disnea. En este episodio se aisló de una muestra respiratoria la cepa HA31Kpn, también productora de metalo-β-lactamasa. HA30pKpn y HA31Kpn fueron resistentes a β-lactámicos (incluidos carbapenémicos y cefalosporinas de tercera y cuarta generación), gentamicina, amicacina, sulfametoxazol, trimetoprima, cloranfenicol, colistina (mutación R256G en gen pmrB) y ciprofloxacina. La paciente fue tratada con altas dosis de tigeciclina y fosfomicina. Evolucionó con descompensación aguda y coma hiperglucémico hiperosmolar y fallece a los 10 días de internación. Ambas cepas fueron secuenciadas por la tecnología MySeq Illumina. El ensamblado y posterior análisis por Bioinformática reveló que ambas cepas pertenecían al secuenciotipo (ST) 11. Además, al analizar los genomas por ResFinder y CARD, encontramos que ambas cepas compartían 17 genes de resistencia a antibióticos aac(6')-Ib-cr, aadA2, aph(3')-Ia, blaCTX-M-15, blaNDM-5, blaOXA-1, blaSHV-182, catB3, dfrA12, mph(A), oqxA, oqxB, qacE, qnrS1, rmtB, sul1, con 100% de identidad a GRA ya descriptos, y el gen fosA que correspondería a un nuevo alelo. La cepa HA30pKpn poseía además el GRA aph(3')-III. Considerando los resultados genotípicos y fenotipos, ambas cepas solo serían sensibles genéticamente a tigecilina, ya que el gen fosA, aunque presente en ambas cepas, no evidenció resistencia a nivel fenotípico. Ambas cepas poseían al replicón Col440I, y al igual que Ec265, compartían los replicones IncFIB y IncFII. También se realizaron ensayos de conjugación.La epidemiología mundial de K. pneumoniae productora de carbapenemasas muestra que diferentes linajes circulan en diferentes regiones geográficas, siendo el ST258 predominante en Europa y EE. UU., y el ST11 más frecuente en Asia oriental, y recientemente fue descripto también en Brasil y en nuestro pais. Aunque en general estos ST están asociados a la diseminación de la carbapenemasa blaKPC-2, nuestros resultados indican la emergencia del ST11 diseminando blaNDM-5, blaCTX-M-15, y rmtB en una misma cepa, con capacidad de colonizar y luego infectar a pacientes en nuestro país.Fil: Masso, Mariana Guillermina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones en Microbiología y Parasitología Médica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones en Microbiología y Parasitología Médica; ArgentinaFil: García Allende, Natalia. Hospital Alemán; ArgentinaFil: Alvarez, Verónica Elizabeth. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones en Microbiología y Parasitología Médica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones en Microbiología y Parasitología Médica; ArgentinaFil: Campos, Josefina. Dirección Nacional de Instituto de Investigación.Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"; ArgentinaFil: Fox, Barbara. Hospital Aleman; ArgentinaFil: Carrera Paez, Laura Camila. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones en Microbiología y Parasitología Médica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones en Microbiología y Parasitología Médica; ArgentinaFil: Fernández Canigia, Liliana. Hospital Alemán; ArgentinaFil: Quiroga, María Paula. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones en Microbiología y Parasitología Médica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones en Microbiología y Parasitología Médica; ArgentinaFil: Centron, Daniela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones en Microbiología y Parasitología Médica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones en Microbiología y Parasitología Médica; ArgentinaXIX Jornadas Argentinas de MicrobiologíaArgentinaAsociacion Argentina de Microbiologi